Ornithine decarboxylase (ODC), the first enzyme in the polyamine biosynthesis, plays an important role in tumor progression, cell proliferation and differentiation. In recent years, ODC has been the subject of intense study among researchers, as a target for anti-cancer therapy and specific inhibitory agents, have the potential to suppress carcinogenesis and find applications in clinical therapy. In particular, it is suggested that ODC is a promising candidate target for natural products in cancer chemoprevention. Future exploration of ornithine decarboxylase inhibitors present in nature may offer great hope for finding new cancer chemopreventive agents.
Introduction
In the validation and selection of molecular targets for therapeutic intervention in cancer, the frequency with which a particular target undergoes mutation or deregulation is a valuable indicator of its importance in the malignancy process and of the potential uses of a drug that acts on that target. Polyamines (putrescine, spermidine, spermine), a group of cell components, have been implicated in the transformation of cell, tumor development, regulation of cell proliferation, cell differentiation and apoptosis. High levels of polyamines are frequently seen in a variety of human malignancies (LaMuraglia et al., 1986; Luk and Casero, 1987; Paz et al., 2011; Soda, 2011) . Ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine biosynthesis, and one of the promising candidate target, plays an important role in tumor progression, cell proliferation and differentiation (Coffino, 2001; Criss, 2003) . It is one of the most highly regulated enzymes in eukaryotic organisms stimulated by a number of factors including hormones, tumor promoters and growth factors (McCann and Pegg, 1992; Verma, 1992) . It is thought that ODC plays role in tumor promotion stage of carcinogenesis, transformation and metastasis of tissues, resulting in increased level of polyamines not only in humans but also in rodents (Verma, 1990; Kubota et al., 1997; Peralta Soler et al., 1998; Shantz and Pegg, 1998; Hurta, 2000; Hardin et al., 2002) . The activity of ODC is controlled by a combinatorial effect of transcription, translation and enzyme degradation. In addition, the activity is specifically inhibited by antizyme protein feed-back regulation by polyamines. Depletion in COMMENTARY Ornithine Decarboxylase: A Promising and Exploratory Candidate Target for Natural Products in Cancer Chemoprevention Suaib Luqman polyamine pools has been shown to provoke pro-apoptotic activity in cancer cells and even prevent metastasis (Pezzuto et al., 2005; Shantz and Levin, 2007) . So, inhibiting ODC activity should not only prevent tumor growth but also stops metastatic progression even in the event of cells escaping environment of the primary tumor. Therefore, ODC has been identified as a potential target in chemotherapy of cancer and parasitic diseases (Pegg et al., 1995) .
Information Retrieval
Exploration of fundamental information was attained from international journals of repute, book chapters, books, reports, abstract, summary available at google (www.google.co.in), SciFinder (https://scifinder.cas. org/), PubMed (www.ncbi.nlm.nih.gov/pubmed/), Science Direct (http://www.sciencedirect.com/) search engines using keywords 'ornithine decarboxylase', 'natural products', 'cancer chemoprevention', 'molecular targets'. Information collected were compiled and arbitrarily used for preparing the commentary.
ODC Inhibitors
Difluoromethylomithine (DFMO), an inhibitor of ODC, has been found effective in essentially all animal models studied (Meyskens and Gerner, 1999) and has been the subject of clinical trials for colon, breast, prostate, skin, esophagus and cervical cancer (Lee and Pezzuto, 1999) . Despite this potential, to the best of my knowledge very few ornithine decarboxylase inhibitors are in development or on the market and only 2-3 among them is being investigated for the treatment of cancer. This exciting target thus deserves further pharmaceutical attention to search for new ODC inhibitors. To accomplish this, natural products especially from plants receive much attention these days as lead molecule followed by chemical modification with improved activity. Some of the most interesting inhibitors belonging to rotenoids, flavonoids, lignans, retinoids, thiols, thiones and diterpene class of compounds were shown to have potent activity by regulating ODC (Table 1; Sharma et al., 1994; Gerhauser et al., 1995) . Some examples like deguelin, tephrosin, hydroxydeguelin, hydroxytephrosin Lee & Pezzuto, 1999 α-difluoromethylornithine ME308 20.000 Lee & Pezzuto, 1999 All trans retinoic acid ME308 2.500 Lee & Pezzuto, 1999 13-cis retinoic acid ME308 1.200 Lee & Pezzuto, 1999 (rotenoids), munetone and mundulone (isoflavones), and mundulinol (flavanol), (+)-7-oxo-l3-epipimara-14,15-dien-18-oic acid, (+)-7-oxo-13-epipimara-8,15-dien-18-oic acid, and (+)-isopimaric acid (diterpenes), (1S,2S,3R)-(+)-isopicrodeoxypodophyllotoxin, (-)-deoxypodophyllotoxin, (-)-deoxypodorhizone, sulforaphane, resveratrol, curcumin, tea catechins and quercetin were found to have strong inhibitory activity against TPA-induced ODC activity (Kato et al., 1983; Lee et al., 1999a; Lee et al., 1999b) whereas zapotin and 5, 6, 2'-trimethoxyflavone exhibited moderate activity (Ito et al., 1998) . Most potent deguelin and sulphoraphane were also found to be active in mouse skin carcinogenesis and rat mammary tumor models Udeani et al., 1997) . Mechanistic studies revealed that deguelin affects TPA-induced transcriptional increase of the ODC gene and TPA-independent c-myc-induced ODC activity in BALB/c c-MycER cells. Deguelin and tephrosin were also found to affect mitochondrial oxidative phosphorylation by inhibiting NADH dehydrogenase activity. It is likely possible that a disturbance of cellular ATP may be the mechanism through which these rotenoids influence tumor promoter-induced signaling mechanisms (Lee et al., 1999b) . Thus, ODC is the subject of intense study among researchers, as a target for anti-cancer therapy and agents that inhibit ODC activity, have the potential to suppress carcinogenesis and have therapeutic potential. It has been anticipated that less than 10% of higher plant species have been screened for biological activity so far, suggesting that nature is a fundamentally untapped rich source for the discovery of new natural product based chemopreventive agents.High diversity of chemicals, structural complexity, and easy access, inexpensive, less toxic, pleiotropic modes of action, low chemo-resistance are some of the major advantages of natural products over rationally designed synthetic drugs. Thus, it is suggested that ODC is a promising exploratory candidate target for natural products in cancer chemoprevention and future exploration of natural products as ornithine decarboxylase inhibitors may offer great hope for finding new cancer chemopreventive agents.
